Biotechnology

Invetech and AiCella Announce Strategic Collaboration to Advance Cell Therapy Innovation

SAN DIEGO, June 27, 2025 /PRNewswire/ -- Invetech, a global leader in solving complex manufacturing and product development challenges in the advanced therapies and diagnostics markets, today announced a strategic collaboration with AiCella, a company focused on harnessing the power of artificial...

2025-06-26 22:55 1847

SineuGene's SNUG01 Receives FDA Orphan Drug Designation for ALS

BEIJING, June 26, 2025 /PRNewswire/ -- SineuGene Therapeutics, a clinical-stage biotechnology company focused on gene therapies for neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its gene therapy, SNUG01, for the trea...

2025-06-26 22:04 1892

Spiber announces new partnerships with Manifattura Sesia and Achille Pinto

YAMAGATA, Japan, June 26, 2025 /PRNewswire/ -- Spiber, a pioneer in man-made protein fibre (ISO 2076), produced using cutting-edge fermentation technology, is proud to announce itsnew partnerships with Manifattura Sesia S.r.l. and Achille Pinto S.p.A.

2025-06-26 20:15 2383

Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia

SHANGHAI, June 26, 2025 /PRNewswire/ -- Alebund Pharmaceuticals  ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for renal diseases and related chronic conditions, announced the database lock was achieved ...

2025-06-26 20:00 1856

Angel Yeast Set to Open Baiyang Biotechnology Park in Yichang in September

YICHANG, China, June 26, 2025 /PRNewswire/ -- Angel Yeast (SH:600298) a global leader in yeast manufacturing, has announced that its Baiyang Biotechnology Park ("the Park") located in the Yichang High-Tech Zone will complete construction and commence trial production i...

2025-06-26 20:00 1951

BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria

* Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal Therapy SHANGHAI, June 25, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has ...

2025-06-26 08:38 5493

Medeologix Sets New Standard with 3-Week Lead Time for PET Heat Shrink Tubing

SAN JOSE, Calif., June 25, 2025 /PRNewswire/ -- Medeologix, a leading brand in medical device manufacturing, today announced a significant advancement in their production capabilities that slashes lead times for premium PET heat shrink tubing to just 3 weeks. This milestone is made possible by M...

2025-06-25 23:00 1694

Senhwa Biosciences Highlights Breakthroughs in Dual First-in-Class Drug Programs at Annual Shareholders' Meeting Today

TAIPEI and SAN DIEGO, June 25, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company, held its 2025 Annual Shareholders' Meeting today, chaired by Chairman Mr.Benny T. Hu. The company delivered updates on its ongoing drug development programs, outl...

2025-06-25 19:00 2164

EDAN Establishes Mexico Subsidiary to Strengthen Presence in the Americas

MEXICO CITY, June 25, 2025 /PRNewswire/ -- EDAN Instruments, Inc. (300206.SZ), a healthcare company and medical device manufacturer, officially celebrated the opening of its new subsidiary, EDAN MEDICAL MÉXICO S de R.L. de C.V., with a ribbon-cutting ceremony held last Wednesday inMexico City. Th...

2025-06-25 18:07 1991

QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA

BRISBANE, Australia, June 25, 2025 /PRNewswire/ --   QBiotics CEO, Stephen Doyle, reflecting on Soft Tissue Sarcoma data * Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate in 11 (10 evaluable) patients with advanced S...

2025-06-25 18:05 1986

£7.5 million Longitude Prize on ALS launches

LONDON, June 25, 2025 /PRNewswire/ -- The Longitude Prize on ALS, a £7.5 million global challenge prize, has launched to incentivise and reward cutting edge AI-based approaches to transform drug discovery for the treatment of ALS (amyotrophic lateral sclerosis), the most common form of MND (motor...

2025-06-25 15:00 2389

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation andglobal market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO, June 25, ...

2025-06-25 12:16 3560

AI Adoption Surges in Life Sciences Manufacturing as Talent, Risk, and Quality Pressures Intensify

Global survey reveals how manufacturers are adopting advanced technologies to stay competitive and meet rising patient demands amid economic uncertainty MILWAUKEE, June 24, 2025 /PRNewswire/ -- Rockwell Automation, Inc.  (NYSE: ROK), the world's largest compa...

2025-06-24 21:00 1922

Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population

NEW YORK, June 24, 2025 /PRNewswire/ -- Klotho Neuroscience, Inc. (NASDAQ: KLTO ), a US-based biogenetics company developing cell and gene- based treatments to address neurological conditions, including ALS, Alzheimer's Disease (AD) and Parkinson's Disease (PD), has announced that it is partnering...

2025-06-24 17:00 2820

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions

* Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes and overweight, non-obese individuals * Preclinical data for BGM1812 supports further development as next-generation amy...

2025-06-24 08:54 2641

Cell Study by SDU and PKU Researchers Reveals Novel Mechanism to Regulate Glucose Metabolism

JINAN, China, June 23, 2025 /PRNewswire/ -- On May 29, 2025, Professor Sun Jinpeng's team and Professor Yu Xiao's team at Shandong University, collaborating with Professor Jiang Changtao from Peking University, Professor Pang Yanli, and Professor Ji Linong, published a research paper entitled "A ...

2025-06-23 17:37 1795

IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy of Neurology (EAN)

SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that results from an ...

2025-06-23 10:01 2209

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a global strategic collabora...

2025-06-23 08:03 2033

Everest Medicines Announces Official Publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025)

SHANGHAI, June 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that theSpecifications for Antimicro...

2025-06-23 07:30 2193

Novogene Establishes New Subsidiary in Korea to Accelerate Multi-Omics Research

SEOUL, South Korea, June 23, 2025 /PRNewswire/ -- Novogene, a global leader in next-generation sequencing (NGS) and multi-omics solutions, today announcedthe establishment ofNovogene Korea Limited, a wholly owned subsidiary headquartered in Seoul. This strategic expansion deepens Novogene's long-...

2025-06-23 05:00 2169
1 ... 34353637383940 ... 341